Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ROHM COMPANY LIMITED    6963   JP3982800009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ROHM : U.S. Patents Awarded to Inventors in Pennsylvania (Nov. 10)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:38pm CET

ALEXANDRIA, Va., Nov. 10 -- The following federal patents were awarded to inventors in Pennsylvania.

***

Dow Global Technologies, Rohm and Haas Assigned Patent for Microbicidal Composition

ALEXANDRIA, Va., Nov. 10 -- Dow Global Technologies, Midland, Michigan, and Rohm and Haas, Philadelphia, have been assigned a patent (9,808,002) developed by seven co-inventors for a microbicidal composition. The co-inventors are Usha Gandhi, Hatboro, Pennsylvania, Christine McInnis, Blue Bell, Pennsylvania, Kiran Pareek, Bensalem, Pennsylvania, Paul O. Schook, Lake Zurich, Illinois, Nigel G. Watson, Chadds Ford Township, Pennsylvania, Terry Michael Williams, Lower Gwynedd, Pennsylvania, and Bei Yin, Phoenixville, Pennsylvania. The abstract states: "An aqueous microbicidal composition having two components. The first component is a nonionic surfactant with structure: R.sup.2O(CH.sub.2CH(CH.sub.3)O).sub.3(CH.sub.2CH.sub.2O).sub.5H, where R.sup.2 is a mixture of C.sub.8-C.sub.14 linear alkyl groups. The second component is a benzoate or sorbate salt. The weight ratio of the nonionic surfactant to the benzoate or sorbate salt is from 1:0.12 to 1:109.7646."

The patent application was filed on May 8, 2017 (15/588,946). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,002.PN.&OS=PN/9,808,002&RS=PN/9,808,002

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Merck Sharp & Dohme Assigned Patent for Pyrrolo[2,3-C]pyridines as Imaging Agents

ALEXANDRIA, Va., Nov. 10 -- Merck Sharp & Dohme, Rahway, New Jersey, has been assigned a patent (9,808,542) developed by 11 co-inventors for "pyrrolo[2,3-C]pyridines as imaging agents for neurofibrillary." The co-inventors are Abbas W. Walji, Lansdale, Pennsylvania, Eric Hostetler, Collegeville, Pennsylvania, Thomas J. Greshock, Collegeville, Pennsylvania, Jing Li, Lansdale, Pennsylvania, Keith P. Moore, Doylestown, Pennsylvania, Idriss Bennacef, Ambler, Pennsylvania, James Mulhearn, Elkins Park, Pennsylvania, Harold Selnick, Ambler, Pennsylvania, Yaode Wang, Beijing, Kun Yang, Beijing, and Jianmin Fu, Beijing. The abstract states: "The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. ##STR00001##."

The patent application was filed on June 9, 2015 (15/317,333). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,542.PN.&OS=PN/9,808,542&RS=PN/9,808,542

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Temptime Assigned Patent for Computing Systems

ALEXANDRIA, Va., Nov. 10 -- Temptime, Morris Plains, New Jersey, has been assigned a patent (9,811,632) developed by six co-inventors for "computing systems and methods for electronically indicating the acceptability of a product." The co-inventors are Frederick Robert Grabiner, Livingston, New Jersey, Carl Michael Lentz, Cedar Knolls, New Jersey, Emily Moore, Haddam, Connecticut, Thaddeus Prusik, Stroudsburg, Pennsylvania, Nicholas Puro, Briarcliff Manor, New York, and Bruce-Erik Osborn, West Vancouver, Canada. The abstract states: "In part, the invention relates to computing systems and methods for electronically indicating the acceptability of a product. An image capture and communication device may analyze a product label that includes one or more monitors, authentication elements, and identification elements. The image capture and communication device may determine the type and features of the monitors, authentication elements, and identification elements. The image capture and communication device may transmit data based on the type and features to a host server, which may transmit data associated with the host product to the image capture and communication device in, inter alia, the form of an acceptability report."

The patent application was filed on Dec. 28, 2015 (14/981,457). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,811,632.PN.&OS=PN/9,811,632&RS=PN/9,811,632

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Merck Sharp & Dohme Assigned Patent for Glycosidase Inhibitors

ALEXANDRIA, Va., Nov. 10 -- Merck Sharp & Dohme, Rahway, New Jersey, and Alectos Therapeutics, Burnaby, Canada, have been assigned a patent (9,809,537) developed by six co-inventors for "glycosidase inhibitors and uses thereof." The co-inventors are Ernest J. McEachern, Vancouver, Canada, Jianyu Sun, Burnaby, Canada, David J. Vocadlo, Burnaby, Canada, Yuanxi Zhou, Burnaby, Canada, Yongbao Zhu, Burnaby, Canada, and Harold G. Selnick, West Point, Pennsylvania. The abstract states: "The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc."

The patent application was filed on Aug. 29, 2013 (14/424,873). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,537.PN.&OS=PN/9,809,537&RS=PN/9,809,537

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Merck Sharp & Dohme Assigned Patent for Preparation, Use of 3-Pyridyl Substituted-6,6-Difluoro Bicyclic Himbacine Derivatives

ALEXANDRIA, Va., Nov. 10 -- Merck Sharp & Dohme, Rahway, New Jersey, has been assigned a patent (9,808,473) developed by four co-inventors for "preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists." The co-inventors are James Francis Dropinski, Freehold, New Jersey, Milana Maletic, Summit, New Jersey, Jae-Hun Kim, Scotch Plains, New Jersey, and Deyou Sha, Yardley, Pennsylvania. The abstract states: "The present invention relates to bicyclic himbacine derivatives of the formula ##STR00001## or a pharmaceutically acceptable salt thereof wherein: R.sup.1 is halo; --CN; alkyl; cycloalkyl; alkoxy; phenyl, which is optionally substituted one or twice independently by alkyl, halo, or --CN; or a thiophene ring, which is optionally substituted once or twice independently by alkyl. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD."

The patent application was filed on Aug. 18, 2014 (14/912,315). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,473.PN.&OS=PN/9,808,473&RS=PN/9,808,473

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bayer Healthcare Assigned Patent for High Pressure Sensor

ALEXANDRIA, Va., Nov. 10 -- Bayer Healthcare, Whippany, New Jersey, has been assigned a patent (9,808,571) developed by four co-inventors for a "high pressure sensor for use with a fluid delivery system." The co-inventors are Michael A. Riley, Saxonburg, Pennsylvania, Gerald W. Callan, Cranberry Township, Pennsylvania, Michael A. Spohn, Fenelton, Pennsylvania, and Michael J. Swantner, Saxonburg, Pennsylvania. The abstract states: "A pressure sensor for use with a fluid delivery system having good sensitivity at low pressure, but also configured to remain in operating condition after being exposed to high pressures is disclosed herein. In one variation, the pressure sensor includes a fluid path set, a deformable element associated with the fluid path set and configured to deform in response to an external pressure, and a pressure transducer for monitoring deformation of the deformable element. In certain embodiments, the pressure sensor is configured to measure fluid pressure within the range of between about 0 mm Hg to about 300 mm Hg. However, the sensor pressure is also be configured to remain functional after being exposed to pressure in excess of about 60,000 mm Hg."

The patent application was filed on Nov. 3, 2016 (15/342,434). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,571.PN.&OS=PN/9,808,571&RS=PN/9,808,571

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Convatec Technologies Assigned Patent for Valve System

ALEXANDRIA, Va., Nov. 10 -- Convatec Technologies, Las Vegas, has been assigned a patent (9,808,606) developed by two co-inventors for a "valve system for inflatable medical device." The co-inventors are Yun Jin, Bridgewater, New Jersey, and Christopher Carter Gregory, Newtown, Pennsylvania. The abstract states: "The present invention relates to a valve system for an inflatable portion of an indwelling medical device and more particularly to a valve system for fluid regulation of a catheter comprising a fluid inflatable portion that undergoes pressure changes within the body during use."

The patent application was filed on June 19, 2015 (14/745,312). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,606.PN.&OS=PN/9,808,606&RS=PN/9,808,606

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,573) developed by six co-inventors for "substituted pyridine derivatives useful as GSK-3 inhibitors." The co-inventors are Guanglin Luo, Madison, Connecticut, Ling Chen, Middletown, Connecticut, Gene M. Dubowchik, Middlefield, Connecticut, Swanee E. Jacutin-Porte, Madison, Connecticut, Prasanna Sivaprakasam, Middletown, Connecticut, and John E. Macor, Washington Crossing, Pennsylvania. The abstract states: "The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system."

The patent application was filed on Nov. 3, 2014 (15/033,770). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,573.PN.&OS=PN/9,809,573&RS=PN/9,809,573

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Dow Global Technologies, Rohm and Haas Assigned Patent for Microbicidal Composition

ALEXANDRIA, Va., Nov. 10 -- Dow Global Technologies, Midland, Michigan, and Rohm and Haas, Philadelphia, have been assigned a patent (9,808,001) developed by seven co-inventors for a microbicidal composition. The co-inventors are Usha Gandhi, Hatboro, Pennsylvania, Christine McInnis, Blue Bell, Pennsylvania, Kiran Pareek, Bensalem, Pennsylvania, Paul O. Schook, Lake Zurich, Illinois, Nigel G. Watson, Chadds Ford Township, Pennsylvania, Terry Michael Williams, Lower Gwynedd, Pennsylvania, and Bei Yin, Phoenixville, Pennsylvania. The abstract states: "A synergistic microbicidal composition having two components. The first component is a nonionic surfactant with structure: R.sup.2O(CH.sub.2CH(CH.sub.3)O).sub.3(CH.sub.2CH.sub.2O).sub.5H, where R.sup.2 is a mixture of C.sub.8-C.sub.14 linear alkyl groups. The second component is 2-bromo-2-nitropropane-1,3-diol. The weight ratio of the nonionic surfactant to 2-bromo-2-nitropropane-1,3-diol is from 1:0.08 to 1:0.12 or 1:0.2 to 1:1.8286."

The patent application was filed on July 28, 2017 (15/662,457). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,001.PN.&OS=PN/9,808,001&RS=PN/9,808,001

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Lummus Technology Assigned Patent for Olefin Conversion Process

ALEXANDRIA, Va., Nov. 10 -- Lummus Technology, Bloomfield, New Jersey, has been assigned a patent (9,809,513) developed by two co-inventors for an olefin conversion process. The co-inventors are Sukwon Choi, Clifton, New Jersey, and Bala Ramachandran, Easton, Pennsylvania. The abstract states: "Processes for the production of olefins are disclosed, which may include: contacting a hydrocarbon mixture comprising linear butenes with an isomerization catalyst to form an isomerization product comprising 2-butenes and 1-butenes; contacting the isomerization product with a first metathesis catalyst to form a first metathesis product comprising 2-pentene and propylene, as well as any unreacted C.sub.4 olefins, and byproducts ethylene and 3-hexene; and fractionating the first metathesis product to form a C3- fraction and a C5 fraction comprising 2-pentene. The 2-pentene may then be advantageously used to produce high purity 1-butene, 3-hexene, 1-hexene, propylene, or other desired products."

The patent application was filed on Nov. 20, 2014 (14/548,475). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,513.PN.&OS=PN/9,809,513&RS=PN/9,809,513

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Merck Sharp & Dohme Assigned Patent for Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity

ALEXANDRIA, Va., Nov. 10 -- Merck Sharp & Dohme, Rahway, New Jersey, has been assigned a patent (9,809,568) developed by seven co-inventors for "compounds inhibiting leucine-rich repeat kinase enzyme activity." The co-inventors are Duane DeMong, Somerset, New Jersey, Michael Miller, Scotch Plains, New Jersey, Hong Liu, Hillsborough, New Jersey, Xing Dai, Cranford, New Jersey, Thomas Greshock, Collegeville, Pennsylvania, Andrew Stamford, Chatham, New Jersey, and Ravi Nargund, East Brunswick, New Jersey. The abstract states: "The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved."

The patent application was filed on Nov. 10, 2014 (15/035,255). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,568.PN.&OS=PN/9,809,568&RS=PN/9,809,568

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

University of Michigan, University of Delaware Assigned Patent for Regenerative Peripheral Nerve Interface

ALEXANDRIA, Va., Nov. 10 -- The University of Michigan, Ann Arbor, Michigan, and the University of Delaware, Newark, Delaware, have been assigned a patent (9,808,616) developed by three co-inventors for the "regenerative peripheral nerve interface." The co-inventors are Paul S. Cederna, Milan, Michigan, Melanie G. Urbanchek, Ann Arbor, Michigan, and David C. Martin, Lincoln University, Pennsylvania. The abstract states: "The present disclosure provides a regenerative peripheral nerve interface (RPNI) for a subject comprising an insulating substrate, at least one metallic electrode deposited onto the insulating substrate forming a thin-film array; a portion of the at least one metallic electrode surface having a layer of a first conductive polymer and a layer of decellularized small intestinal submucosa (SIS) coating a portion of the electrode, wherein a second conductive polymer is electrochemically polymerized through the SIS to form the regenerative peripheral nerve interface. The present disclosure also provides that a layer of muscle tissue contacts the regenerative peripheral nerve interface."

The patent application was filed on Jan. 13, 2012 (13/979,507). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,616.PN.&OS=PN/9,808,616&RS=PN/9,808,616

Written by Amal Ahmed; edited by Sudarshan Harpal.

TARGETED NEWS SERVICE: Myron Struck, editor; 703/304-1897; [email protected]; http://www.targetednews.com

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROHM COMPANY LIMITED
06:07p OMAN LEISURE : ROHM’s legendary performances in December
11/13 ROHM : Monthly Sales Information updated.
11/11 ROHM : U.S. Patents Awarded to Inventors in Michigan (Nov. 11)
11/10 ROHM : U.S. Patents Awarded to Inventors in Pennsylvania (Nov. 10)
10/24 OMAN LEISURE : ROHM’S legendary performances in November
10/24 ROHM : Global Vises Market by Key players (Wilton, GRESSEL, Raptor Work holding ..
10/24 ROHM : Analyst Coverage updated.
10/11 ROHM : Monthly Sales Information updated.
10/03 OMAN LEISURE : ROHM’s legendary performances for October
09/27 ROHM COMPANY LIMITED : Anniversary bonus dividend
More news
News from SeekingAlpha
06/02 It Was A Great May For Chip Stocks
2015 Tech Vulnerability To Strong Dollar
Financials ( JPY)
Sales 2018 396 B
EBIT 2018 -
Net income 2018 42 554 M
Finance 2018 301 B
Yield 2018 1,95%
P/E ratio 2018 31,58
P/E ratio 2019 26,37
EV / Sales 2018 2,72x
EV / Sales 2019 2,54x
Capitalization 1 380 B
Chart ROHM COMPANY LIMITED
Duration : Period :
ROHM COMPANY LIMITED Technical Analysis Chart | 6963 | JP3982800009 | 4-Traders
Technical analysis trends ROHM COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 11 939  JPY
Spread / Average Target -3,8%
EPS Revisions
Managers
NameTitle
Satoshi Sawamura President & Representative Director
Ken Sato Director
Eiichi Sasayama Director, General Manager-Accounting & IR Contact
Tadanobu Fujiwara Director & General Manager-Local Sales
Hachiro Kawamoto Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ROHM COMPANY LIMITED84.40%12 264
INTEL CORPORATION23.05%208 822
TAIWAN SEMICONDUCTOR MFG. CO. LTD.--.--%206 015
NVIDIA CORPORATION98.01%128 448
BROADCOM LIMITED53.79%112 145
TEXAS INSTRUMENTS33.95%96 861